← All trials
NCT02539277
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2014
- Primary completion
- Nov 1, 2015
- Completion date
- Nov 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- Changchun University of Chinese MedicineCollaborator
- Shandong University of Traditional Chinese MedicineCollaborator
- China Academy of Chinese Medical SciencesCollaborator
- Capital Medical UniversityCollaborator
- Heilongjiang University of Traditional Chinese MedicineCollaborator
- China Academy of Chinese Medical SciencesReponsible party - principal investigator
- China Academy of Chinese Medical SciencesStudy chair
- Guangdong Provincial Hospital of Traditional Chinese MedicineCollaborator
- Liaoning Hospital of Traditional Chinese MedicineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.